Spread of the disease NUTS 3 areas with at least one ASF notification during the reporting period |
|
Surveillance (samples tested for ASF) in whole country during reporting period | Passive surveillance in WB* | Passive surveillance in DP* | ||||
Diagnostic test(s) used | Total samples | Positive samples | Diagnostic test(s) used | Total samples | Positive samples | |
PCR | 65 | 20 | PCR | 3,959 | 3 | |
ELISA | 6 | 1 | ELISA | 158 | 0 | |
ELISA + IPT | 1 | 1 | ELISA + IPT | 0 | NA | |
ELISA + IB | 0 | NA | ELISA + IB | 0 | NA | |
Active surveillance in WB* | Active surveillance in DP* | |||||
Diagnostic test(s) used | Total samples | Positive samples | Diagnostic test(s) used | Total samples | Positive samples | |
PCR | 10,081 | 12 | PCR | 1,011 | 0 | |
ELISA | 10,069 | 75 | ELISA | 61 | 0 | |
ELISA + IPT | 75 | 64 | ELISA + IPT | 0 | NA | |
ELISA + IB | 0 | NA | ELISA + IB | 0 | NA | |
Surveillance (samples tested for ASF) in NUTS 3 areas with at least one ASF notification during the reporting period | Passive surveillance in WB* | Passive surveillance in DP* | ||||
Diagnostic test(s) used | Total samples | Positive samples | Diagnostic test(s) used | Total samples | Positive samples | |
PCR | 28 | 20 | PCR | 1,213 | 3 | |
ELISA | 2 | 1 | ELISA | 14 | 0 | |
ELISA + IPT | 1 | 1 | ELISA + IPT | 0 | NA | |
ELISA + IB | 0 | NA | ELISA + IB | 0 | NA | |
Active surveillance in WB* | Active surveillance in DP* | |||||
Diagnostic test(s) used | Total samples | Positive samples | Diagnostic test(s) used | Total samples | Positive samples | |
PCR | 1,975 | 12 | PCR | ND | ND | |
ELISA | 1,976 | 27 | ELISA | ND | ND | |
ELISA + IPT | 27 | 23 | ELISA + IPT | ND | ND | |
ELISA + IB | 0 | NA | ELISA + IB | ND | ND |
ND: no data provided to EFSA; NA: Not applicable.
*: See Section 3.1.1 for definitions.